Kinetics of COVID-19 mRNA primary and booster vaccine-associated neutralizing activity against SARS-CoV-2 variants of concern in long-term care facility residents: a prospective longitudinal study in Japan

Table 2. Multiple regression analyses to investigate factors responsible for the variation in IgG (S-RBD) and neutralizing activities against the wild-type virus and the Delta and Omicron variants

The levels of each of the antibodies to the receptor-binding domain (RBD) of the S1 subunit of the viral spike protein [IgG (S-RBD)] and neutralizing activities were set as objective variables, and the following factors were considered as candidate explanatory variables: age, sex, number of comorbidities, immunosuppression (binary), Eastern Cooperative Oncology Group Performance Status Scale (ECOG-PS), serum albumin, estimated glomerular filtration rate (e-GFR), and glycated hemoglobin (HbA1c). The values presented in the table are r_p of statistical significance (P < 0.05) except for that in the column of n (data size) and R (multiple regression coefficient). Values of R ≥ 0.5 are shown in bold. The values of |r_p| are shown in three graded background colors: orange if positive and blue if negative. The graded color corresponds to slight (0.2 ≤|r_p|< 0.3), moderate (0.3 <|r_p|< 0.5), and strong (0.5 ≤|r_p|) correlations
^*1 The antibody level was logarithmically transformed before the analysis
^*2 The neutralizing activity was transformed into a ranking scale to correct for highly skewed distribution before the analysis
^*3 The dummy variable "sex" was coded as male = 0 and female = 1
^*4 Immunosuppression included receiving steroids, immunosuppressive agents, chemotherapy, or biologic therapy

ISSN: 1742-4933